Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global hepatocellular carcinoma market was pegged at US$ 14 billion in 2021 and is expected to register a revenue CAGR of 11.5% to reach US$ 41.57 billion by 2030.

Market Fundamentals 

Numerous therapies are being investigated for the highly prevalent and deadly malignancy known as hepatocellular carcinoma. Given its inflammatory origins, can potentially be a tumor with a strong immune response. Anti-programmed death-1 monotherapies were the first immunotherapies, and they increased survival and response rates. Immunotherapy and novel immunotherapy combinations have promise as first-line treatments. Atezolizumab plus bevacizumab, a breakthrough antibody treatment combo, could revolutionize medical care. The function of immunotherapy in the context of liver transplantation is questionable until the safety of this method is established, despite the fact that this ground-breaking research offers new treatment alternatives.

[76328742]

Market Dynamics 

The hepatocellular carcinoma market revenue is driven by the rise in hepatocellular carcinoma incidence and mortality from liver cancer around the world. In the United States, around 42,030 new individuals are expected to receive a liver cancer diagnosis in 2019. Three-fourths of these would oversee hepatocellular carcinoma. Furthermore, it is estimated that 31,780 Americans lost  their lives to liver cancer in 2019. The global market for hepatocellular carcinoma is expected to grow during the forecast period because of changing lifestyles, obesity, high blood pressure, diabetes, and an increase in geriatric patients. Additionally, new product launches and partnerships among key players operating in the market are also likely to drive the global market revenue. 

Market Ecosystem 

The global hepatocellular carcinoma market has been analyzed from two perspectives: by marketed drugs and regions. 

Hepatocellular Carcinoma Market by Marketed Drugs

[3123123]

Based on marketed drugs, the global hepatocellular carcinoma market is segmented into Sorafenib (Nexavar), Nivolumab (Opdivo), Bevacizumab (Avastin), Regorafenib (Stivarga), Lenvatinib Mesylate (Lenvima), Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Cabozantinib (Cabometyx), Ramucirumab (Cyramza) and Miriplatin (Miripla). 

The Atezolizumab (Tecentriq) segment dominates the market during the forecast period. Chemotherapies, accessible for more than ten years, have historically formed the foundation of the HCC industry. However, because of recent events, scientists are investigating brand-new mechanisms of action (MOAs) to address the large proportion of patients who do not respond to treatment. The introduction of new medications, most of which are expected to launch between 2023 and 2026 and target the moderate-to-severe patient population, will contribute to a significant rise in market revenue share. Due to their superior clinical profile, biologics, including anti-PD-1 and PD-L1 inhibitors, are gaining ground in the HCC market.

Hepatocellular Carcinoma Market by Region 

Based on region, the global hepatocellular carcinoma has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America accounts for the largest market revenue share. This rise in revenue share is due to an increase in hepatocellular carcinoma prevalence, an increase in the number of deaths from the disease in the United States, and an increase in the number of clinical studies manufacturers are doing there.

Furthermore, during the forecast period, European is expected to rise significantly with a high revenue share. 

The primary driver of the hepatocellular carcinoma market in Asia Pacific is the rise in the prevalence of hepatitis B and C, which causes the development of HCC in growing nations like India and China. Additionally, Hepatocellular carcinoma risk is increased by the growing baby boomer generation as well as the rising prevalence of lifestyle illnesses like obesity and diabetes. The need for hepatocellular carcinoma in the area is expected to increase as a result. 

The market for hepatocellular carcinoma in the Middle East and Africa is expected to grow as a result of the high frequency of viral hepatitis that causes chronic liver disease in Africa.

Competitive Landscape 

The prominent players operating in the global hepatocellular carcinoma market are: 

• Bayer AG
• Bristol-Myers Squibb
• Genentech Inc.
• Eisai Inc.
• Merch & Co. Inc.
• Eli Lilly & Company
• Dainippon Sumitomo Pharma

Major industry players are projected to conduct more clinical studies for hepatocellular carcinoma, which is leading to huge market potential. However, in the coming years, the market for hepatocellular carcinoma is expected to be constrained by pharmacological side effects and a strict regulatory environment.

Strategic Development 

• In May 2020, Atezolizumab and bevacizumab (Tecentriq) were approved by the Food and Drug Administration for use in patients with metastatic or unresectable hepatocellular carcinoma who have not previously received systemic therapy, according to a statement from Roche. The IMbrave150 (NCT03434379) trial, a multicenter, multinational, open-label, randomized trial in patients with locally advanced, unresectable, or metastatic hepatocellular carcinoma who had not previously undergone systemic therapy, served as the foundation for the approval.
• In May 2019, Eli Lilly and Company reported that the Food and Drug Administration had approved ramucirumab (Cyramza) as a single treatment for hepatocellular carcinoma (HCC) in people who have had sorafenib treatment in the past and have an alpha-fetoprotein (AFP) level below 400 ng/mL. The REACH2 (NCT02435433) study, which included 292 patients with advanced HCC and an AFP of less than 400 ng/mL and who either progressed on or after sorafenib or was intolerable, served as the foundation for the approval.
• In November 2018, the Food and Drug Administration approved pembrolizumab (Keytruda) for patients with hepatocellular carcinoma (HCC) who have previously received sorafenib treatment, according to a statement from Merck & Co., Inc. The KEYNOTE 224 (NCT02702414) single-arm, multicenter trial that included 104 patients with hepatocellular carcinoma served as the foundation for the approval.

Frequently Asked Questions About This Report